The settlement, reached April 27, resolves allegations that from 2010 to 2015, Indivior promoted Suboxone to physicians who prescribed it without a legitimate medical purpose. It also settles allegations that Indivior made misleading claims about Suboxone’s risk of diversion, abuse and accidental pediatric exposure.
Additionally, the settlement resolves allegations that Indivior fraudulently informed the FDA that the drug had been discontinued to deter generic competitors from entering the market.
Last November, Indivior agreed to permanently disband its Suboxone sales force and take steps to prevent promoting it to healthcare providers at high risk of inappropriate prescribing.
In an April 28 news release, Indivior said the settlement announcement was “administrative in nature” and formalized agreements regarding Suboxone marketing it had made last November.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
